Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000412 | 0.87 | — | — | |
| SCHEMBL558492 | 0.85 | PARP1 (0.36) | ALDH1A1 | |
| SCHEMBL211528 | 0.75 | ALDH1A1 (0.44) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL6098342 | 0.75 | KDM4E (0.39) | ALDH1A1TSHRTDP1 | |
| SCHEMBL10411212 | 0.74 | — | — | |
| SCHEMBL558187 | 0.71 | BCAT2 (0.32) | ALDH1A1 | |
| SCHEMBL558555 | 0.71 | PSMB8 (0.44) | ALDH1A1TSHRTDP1 | |
| SCHEMBL558291 | 0.71 | SMN1; SMN2 (0.44) | ALDH1A1TSHRTDP1 | |
| SCHEMBL124933 | 0.71 | PDPK1 (0.44) | CA2ALDH1A1TSHRTDP1 | |
| SCHEMBL1696135 | 0.71 | PSMD14 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0594047-B1 | Arylazo chromoionophores | BAYER AG (US) | 2000-01-05 | — | — | EP | claimed |
| EP-0594047-A1 | Arylazo chromoionophores | Bayer Corporation (US) | 1994-04-27 | — | — | EP | claimed |
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | BAENTELI ROLF | 2007-10-25 | — | — | US | disclosed |
| EP-1734968-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097135-A2 | USE OF 9H-PURINE-2,6-DIAMINE DERIVATIVES IN THE TREATMENT OF PROLIFERATIVE DISEASES AND NOVEL 9H-PURINE-2,6-DIAMINE DERIVATIVES | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
| EP-1329160-A2 | 4-ACYLAMINOPYRAZOLE DERIVATIVES | Sankyo Company, Limited (JP) | 2003-07-23 | — | — | EP | disclosed |
| EP-1313804-A2 | MIXTURE OF OLEFIN POLYMERS AND NITRILE RUBBERS | Bayer Aktiengesellschaft (DE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016492-A2 | MIXTURE OF OLEFIN POLYMERS AND NITRILE RUBBERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-02-28 | — | — | WO | disclosed |
| EP-0594047-B1 | Arylazo chromoionophores | BAYER AG (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0594047-A1 | Arylazo chromoionophores | Bayer Corporation (US) | 1994-04-27 | — | — | EP | disclosed |
| US-5272213-A | Scorch retardant polyacrylate elastomers | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1993-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249639-A1 | Use of 9H-Purine-2,6-Diamine Derivatives in the Treatment of Proliferative Diseases and Novel 9H-Purine-2,6-Diamine Derivatives | HPRT1, NUDT1, DPYD | CA2 4341/4885GABRA1 4197/4885GABRB2 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.